63814-25-5 Usage
Type
Synthetic prostaglandin E1 analog
Primary use
Prevention and treatment of gastric ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs)
Mechanism of action
Reduces stomach acid production and increases protective mucus production
Additional use
Medical abortion in combination with mifepristone
Physiological effects
Stimulates uterine contractions, lowers intraocular pressure
Potency
Potent drug with a wide range of physiological effects
Precaution
Should be used cautiously due to potential side effects
Side effects
Diarrhea, abdominal pain, uterine bleeding
Administration
Oral (for gastric ulcer treatment) and vaginal (for medical abortion)
Pregnancy category
Not to be used during pregnancy due to risk of uterine contractions and potential for abortion
Overdose symptoms
Severe diarrhea, abdominal pain, and uterine bleeding (if used during pregnancy)
Drug interactions
May interact with other medications, including NSAIDs, anticoagulants, and antiplatelet drugs
Storage
Store in a cool, dry place, away from light and moisture
Manufacturer
Various pharmaceutical companies produce misoprostol under different brand names
Availability
Available by prescription in many countries
Cost
Varies depending on the country, insurance coverage, and the specific formulation (e.g., tablet, oral solution)
Check Digit Verification of cas no
The CAS Registry Mumber 63814-25-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,3,8,1 and 4 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 63814-25:
(7*6)+(6*3)+(5*8)+(4*1)+(3*4)+(2*2)+(1*5)=125
125 % 10 = 5
So 63814-25-5 is a valid CAS Registry Number.
InChI:InChI=1/C22H30O5/c23-17(14-16-8-4-3-5-9-16)12-13-19-18(20(24)15-21(19)25)10-6-1-2-7-11-22(26)27/h1,3-6,8-9,17-19,21,23,25H,2,7,10-15H2,(H,26,27)/b6-1-/t17?,18-,19-,21-/m1/s1
63814-25-5Relevant articles and documents
P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
-
, (2008/06/13)
The p-biphenyl esters of 15-substituted-ω-pentanorprostaglandins are disclosed. The novel prostaglandin esters of the invention exhibit the biological properties of corresponding prostaglandins from which they are derived, but have reduced side effects, and are further valuable because they are easily crystallized and thus may be simply isolated and purified and compounded into medicaments.
